ABCG2 and acute myeloid leukemia: We aimed to examine the effect of the CDKI abemaciclib, palbociclib, and ribociclib on pharmacokinetic mechanisms driving AML multidrug resistance through drug efflux via ABC transporters or its metabolism with CREs.